|
|
|
|
||
The setup and the strategyNall, Moskowitz, and Kennedy must certainly have put together an enterprising strategy to optimize subscription to the shareholder's rights offering. I know I would - it's really the only way it can work. The way I see it, there are a lot of pissed off existing shareholders that will require some convincing persuasion to even consider participation, and that persuasion almost necessarily has to take the form of a PR that introduces the promise of structured revenue, structured reimbursement, a partnering deal, or a structured commercial collaboration with the teeth of near-term monetization - and perhaps even a combination of a few of these ingredients - PR'ed over the course of the next few weeks...necessarily wrapping into a tidy and convincing sales package by the 8/8 closing date. This thread discusses some options to anticipate in the coming weeks. A TMO deal, a China deal, or the introduction of a heretofore unannounced partnering enterprise are my obvious first picks. The Alliance Global/Dubai deal isn't enough to stand on it's own merit for the near term. AGBL is a private holding - I can't find much info on their revenues or their partnering successes, though they have some powerhouse partners under their belt... Illumina, for one...AGBL is an authorized distributor. There's at least a hint of credibility in that... In structured reimbursement, the only victory that makes sense to me is admission to the Palmetto/ Noridian MolDx. The CPT codes have been in place for quite some time, though not guaranteed due to "insufficiency of evidence." Definition of "sufficient evidence" remains elusive and subject to administrative interpretation. A MolDx underwriting of the Oncocee assay would be optimal...but a regional underwriting by another large multi-state or regional healthcare provider might also have teeth. Nall will be sharing data on 14K patient samples in Sept at PMWC Duke. It's possible that some part of that data pool will be published earlier than that conference, if only in pursuit of reimbursements. Unsupported by strong reinforcement of impending growth, I'd expect the offering to stagnate and die on the vine... ...leaving the door open for another massive dilution. These guys have gotta put forth their best spin to make this work. Their existence as a going concern depends on it. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
1220 | Re: The setup and the strategy | wilderguide | 0 | 7/17/2018 2:43:22 PM |